Gastric and Gastroesophageal Junction Adenocarcinoma - 5EU Drug Forecast and Market Analysis to 2024 - Research and Markets

Research and Markets has announced the addition of the "Gastric and Gastroesophageal Junction Adenocarcinoma - 5EU Drug Forecast and Market Analysis to 2024" report to their offering.

Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer death in the world. The major treatments for G/GEJAC are chemotherapy-based, but targeted therapies such as HER2 and angiogenesis inhibitors have been approved and are being added to chemotherapy regimens since 2010 and 2014, respectively.

The author expects that the cost consciousness of the 5EU healthcare systems, as well as the difficulties in getting reimbursement approval in individual 5EU countries, will limit the growth of the G/GEJAC market. For example, the high price of Cyramza in the US relative to Herceptin received criticism from interviewed EU KOLs. The author expects that, if Eli Lilly imposes the same pricing strategy for Cyramza in the 5EU, it will have difficulty obtaining reimbursement approval. This kind of reimbursement requirement will slow down the growth of the 5EU G/GEJAC market.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

5.1 Overview

5.2 HER2-Targeted Therapy

5.2.1 Herceptin (trastuzumab)

5.3 Angiogenesis Inhibitors

5.3.1 Cyramza (ramucirumab)

5.3.2 Aitan (apatinib)

5.4 Chemotherapies

5.4.1 TS-1 (tegafur, gimeracil, oteracil)

5.4.2 Abraxane (nab-paclitaxel)

6 Unmet Need and Opportunity

6.1 Overview

6.2 First-Line Therapy for HER2-Negative Patients

6.3 New Molecular Targets for Targeted Therapies

6.4 Effective Perioperative and Postoperative Therapies

6.5 More Efficacious HER2-Targeted Therapies

6.6 Peritoneal Metastases

6.7 Better Clinical Trial Design

6.8 Early Detection of Gastric and Gastroesophageal Adenocarcinomas

7 Pipeline Assessment

7.1 Overview

7.2 Promising Drugs in Phase III Clinical Development

7.3 HER2-Targeted Therapies

7.3.1 Kadcyla (T-DM1; trastuzumab emtansine)

7.3.2 Perjeta (pertuzumab)

7.4 Immune Checkpoint Inhibitors

7.4.1 Keytruda (pembrolizumab)

7.4.2 Opdivo (nivolumab)

7.5 Further Strategies for G/GEJAC Treatment

7.5.1 Napabucasin

7.5.2 Lynparza (olaparib)

7.5.3 Nimotuzumab

7.5.4 TAS-118

7.6 Early/Near-Phase III Pipeline Drugs

7.6.1 GS-5745

7.6.2 Masitinib

7.7 Promising Drugs in Early-Stage Development

7.7.1 Immune Checkpoint Inhibitors

7.7.2 MET-Targeting Drugs

7.7.3 Antibody-Drug Conjugates

7.8 Biosimilars

8 Market Outlook

9 Appendix

For more information about this report visit http://www.researchandmarkets.com/research/x25xnf/gastric_and

View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006296/en/